Alexandra Snyder Charen, MDSloan-Kettering Institute for Cancer Researchr Chemotherapy, Somatic Mutations, and Neoantigens in Ovarian Cancer Immunotherapy is a new treatment that boosts a patient’s immune system to attack ovarian cancer cells. Dr. Synder Charen’s lab has already shown in melanoma that when a tumor has a large number of genetic abnormalities (mutations), the immune […]
Read More
Elizabeth Poole, PhDBrigham and Women’s Hospital2015 Skacel Family Scholar Medication use and ovarian cancer survival Although factors that contribute to ovarian cancer risk prior to diagnosis are currently being teased apart, factors which contribute to survival after a diagnosis of ovarian cancer have not yet been well studied. Dr. Poole’s project will develop the Nurses’ […]
Read More
Benjamin Izar, MD, PhDDana-Farber Cancer Institute Single-cell transcriptome analysis of treatment-resistant ovarian cancer and new strategies for drug discovery Dr. Izar will be studying in fine detail the molecular changes that take place from the time that ovarian cancer cells respond to platinum chemotherapy to when they become resistant. He will employ an innovative genetic […]
Read More
Mark Eckert, PhDUniversity of Chicago Targeting T-LAK cell-originated protein kinase (TOPK) for ovarian cancer therapy Ovarian cancer is one of the most lethal cancers due to a lack of effective therapies. Dr. Eckert’s lab recently found that the protein T-LAK cell-originated protein kinase (TOPK) is expressed in ovarian cancer cells, but not most normal tissues. […]
Read More
Remi Buisson, PhDMassachusetts General Hospital Unraveling the role of ATR in DNA repair and ovarian cancer therapy Proteins involved in the surveillance of genomic integrity, including BRCA1, BRCA2, and PALB2, help detect damage to DNA in cells and ensure that repairs are made when needed. Cells with mutations in BRCA1, BRCA2, and PALB2 have been […]
Read More
Yang Yang-Hartwich, PhDYale University2015 Cookie Laughlin Bridge Funding Award Targeting p53-regulated Twist1 Degradation to Inhibit Ovarian Cancer Metastasis Metastasis is a hallmark of advanced high-grade serous ovarian carcinoma. Turning off the ability of ovarian cancer to spread or metastasize to other places in the body would provide better therapies and prevent recurrence. The objective of […]
Read More
Cheng Wang, PhDUniversity of Nebraska Medical Center2015 Barbara Learned Bridge Funding Award The Hippo/YAP Signaling Pathway in Ovarian High Grade Serous Carcinoma Knowing where and how ovarian cancer starts will lead to earlier detection and better therapies. Recent studies have identified the fallopian tube secretory epithelial cell as the origin for high-grade serous ovarian carcinoma, […]
Read More
Paul Campagnola, PhDUniversity of Wisconsin – Madison2015 Joanie Warner Bridge Funding Award Quantitative Assessment of the Role of Collagen Alterations in Ovarian Cancer High grade serous ovarian cancer arises from fallopian tube cells that migrate and implant on the ovaries, then subsequently metastasize to other sites in the body. The 3-dimensional composition and architecture of […]
Read More
Tomer Shlomi, PhDTechnion Institute (Israel) Targeting ovarian cancer via MTAP synthetic lethality Ovarian cancer cells are genetically unstable. A deletion of the gene MTAP, which is involved in methionine metabolism, is found in 3-15% of ovarian tumors. As a result, affected ovarian cancer cells have lost a functional enzyme for metabolizing old proteins which is […]
Read More
Lilie Lin, MDUniversity of Pennsylvania School of Medicine Pilot study of a novel PARP inhibitor PET tracer in patients with ovarian carcinoma Targeted agents such as poly-ADP ribose polymerase (PARP) inhibitors are actively being tested alone or in combination with chemotherapy or radiotherapy as promising treatments for ovarian cancer. However, not all patients will respond […]
Read More